Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

Chimeric Antigen Receptor (CAR) T cell therapies – adoptive T cell therapies that have been genetically engineered for a new antigen-specificity - have displayed significant success in treating patients with hematologic malignancies, leading to three recent US Food and Drug Administration approvals....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Immunother Cancer
Glavni autori: Boyiadzis, Michael M., Dhodapkar, Madhav V., Brentjens, Renier J., Kochenderfer, James N., Neelapu, Sattva S., Maus, Marcela V., Porter, David L., Maloney, David G., Grupp, Stephan A., Mackall, Crystal L., June, Carl H., Bishop, Michael R.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2018
Teme:
Review
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6278156/
https://ncbi.nlm.nih.gov/pubmed/30514386
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0460-5
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items